Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
2011

Targeting Canine Bladder Cancer with a Human-Specific Ligand

publication Evidence: moderate

Author Information

Author(s): Lin Tzu-yin, Zhang Hongyong, Wang Sisi, Xie Li, Li Bin, Rodriguez Carlos O Jr, de Vere White Ralph, Pan Chong-xian

Primary Institution: University of California-Davis Cancer Center

Hypothesis

Can a human bladder cancer-specific peptide named PLZ4 target canine bladder cancer cells?

Conclusion

PLZ4 can specifically bind to canine bladder cancer cells, suggesting its potential for diagnostic and therapeutic applications.

Supporting Evidence

  • PLZ4 showed high affinity and specific binding to canine bladder TCC cell lines.
  • No significant changes in cell viability were observed with PLZ4 treatment.
  • PLZ4 accumulated significantly at tumor sites in a mouse model compared to controls.

Takeaway

Scientists found a special peptide that can stick to cancer cells in dogs, which might help in treating their bladder cancer.

Methodology

The study used whole cell binding assays, affinitofluorescence assays, and in vivo imaging in a mouse xenograft model.

Limitations

The study primarily focuses on in vitro and mouse models, which may not fully represent canine bladder cancer in clinical settings.

Participant Demographics

Canine bladder cancer cell lines were used, but specific demographic details of the dogs were not provided.

Statistical Information

P-Value

0.003

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/1476-4598-10-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication